Misonix expanded its capabilities to address the orthoplastics market by incorporating its Sequel line of external fixators as a complement to its existing wound debridement and regenerative products.
The company markets BoneScalpel and SonaStar to facilitate precise bone sculpting and removal of soft and hard tumors and tissue, with application in orthopedics. The company also sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service.
SonicOne ultrasonic wound debridement will complement external fixation for the treatment of Charcot foot.
Stavros Vizirgianakis, President and CEO, said, “We now have a compelling suite of complementary products centered around the Misonix SonicOne® wound debridement system, including our new Sequel external fixation system and various reconstructive tissue solutions, such as the TheraGenesis bi-layer tissue matrix, that enhance our ability to address the significant and growing opportunity we see in the orthoplastics market. By creating a more encompassing offering, we not only significantly increase our average revenue per procedure, but also further enhance physicians’ ability to ensure positive patient outcomes.”
Misonix expanded its capabilities to address the orthoplastics market by incorporating its Sequel line of external fixators as a complement to its existing wound debridement and regenerative products.
The company markets BoneScalpel and SonaStar to facilitate precise bone sculpting and removal of soft and hard tumors and tissue, with...
Misonix expanded its capabilities to address the orthoplastics market by incorporating its Sequel line of external fixators as a complement to its existing wound debridement and regenerative products.
The company markets BoneScalpel and SonaStar to facilitate precise bone sculpting and removal of soft and hard tumors and tissue, with application in orthopedics. The company also sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service.
SonicOne ultrasonic wound debridement will complement external fixation for the treatment of Charcot foot.
Stavros Vizirgianakis, President and CEO, said, “We now have a compelling suite of complementary products centered around the Misonix SonicOne® wound debridement system, including our new Sequel external fixation system and various reconstructive tissue solutions, such as the TheraGenesis bi-layer tissue matrix, that enhance our ability to address the significant and growing opportunity we see in the orthoplastics market. By creating a more encompassing offering, we not only significantly increase our average revenue per procedure, but also further enhance physicians’ ability to ensure positive patient outcomes.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
